Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones

Journal of Medicinal Chemistry

Volumn 46, Issue 13, 2003, Pages 2580-2588

  Sohn, Jungsan ^a   Kiburz, Brendan ^a   Li, Zhitao ^a   Deng, Liu ^a   Safi, Alexias ^a   Pirrung, Michael C ^a   Rudolph, Johannes ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIHYDROXY 3 (1H INDOL 3 YL)[1,4]BENZOQUINONE; 2,5 DIHYDROXY 3 (4,6 DICHLORO 7 FARNESYL 1H INDOL 3 YL)[1,4]BENZOQUINONE; 2,5 DIHYDROXY 3 (7 FARNESYL 1H INDOL 3 YL)[1,4]BENZOQUINONE; 3 [4,6 DICHLORO 7 (3 METHYLBUT 2 ENYL) 1H INDOL 3 YL] 2,5 DIHYDROXY [1,4]BENZOQUINONE; 3 [6 CHLORO 7 (3 METHYLBUT 2 ENYL) 1H INDOL 3 YL] 2,5 DIHYDROXY [1,4]BENZOQUINONE; COMPOUND 5; ENZYME INHIBITOR; INDOLYLDIHYDROXYQUINONE; ISOENZYME; NSC 668394; NSC 95397; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE A; PROTEIN TYROSINE PHOSPHATASE B; PROTEIN TYROSINE PHOSPHATASE C; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; CELL DEATH; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; ENZYME MODIFICATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; INHIBITION KINETICS; MUTATION; STRUCTURE ACTIVITY RELATION;

BINDING SITES; CDC25 PHOSPHATASE; CELL LINE; ENZYME INHIBITORS; HUMANS; INDOLES; ISOENZYMES; MODELS, MOLECULAR; QUINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037777745     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0300835     Document Type: Article

References (53)

1. Nigg, E. A. Cyclin-Dependent Protein Kinases: Key Regulators of the Eukaryotic Cell Cycle. BioEssays 1995, 17, 471-480.
2. Nilsson, I.; Hoffman, I. Cell cycle regulation by the Cdc25 phosphatase family. Prog. Cell Cycle Res. 2000, 4, 107-114.
3. Galaktionov, K.; Lee, A. K.; Eckstein, J.; Draetta, G.; Meekler, J.; Loda, M.; Beach, D. Cdc25 Phosphatases as Potential Human Oncogenes. Science 1995, 269, 1575-1577.
4. Galaktionov, K.; Chen, X.; Beach, D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996, 382, 511-517.
5. Cangi, M. G.; Cukor, B.; Soung, P.; Signoretti, S.; Moreira, G., Jr.; Ranashinge, M.; Cady, B.; Pagano, M.; Loda, M. Role of the Cdc25A phosphatase in human breast cancer. J. Clin. Invest. 2000, 106, 753-761.
6. Kudo, Y.; Yasui, W.; Ue, T.; Yamamoto, S.; Yokozaki, H.; Nikai, H.; Tahara, E. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn. J. Cancer Res. 1997, 88, 9947-952.
7. Dixon, D.; Moyana, T.; King, M. J. Elevated expression of the cdc25A protein phosphatase in colon cancer. Exp. Cell Res. 1998, 240, 236-243.
8. Hernández, S.; Bessa, X.; Hernandez, L.; Nadal, A.; Mallofré, C.; Muntane, J.; Castells, A.; Fernandez, P. L.; Cardesa, A.; Campo, E. Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab. Invest. 2001, 81, 465-473.
9. Wu, W. G.; Fan, Y. H.; Kemp, B. L.; Walsh, G.; Mao, L. Over-expression of cdc25A and cdc25B is frequent in primary nonsmall cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 1998, 58, 4082-4085.
10. Hernández, S.; Hernández, L.; Bea, S.; Pinyol, M.; Nayach, I.; Bellosillo, B.; Nadal, A.; Ferrer, A.; Fernandez, P. L.; Montserrat, E.; Cardesa, A.; Cardes, E.; Campo, E. cdc25A and the splicing variant cdc25B2, but not cdc25B1, -B3 or -C, are overexpressed in aggressive human non-Hodgkin's lymphomas. Int. J. Cancer 2000, 89, 148-152.
11. Ma, Z.-Q.; Chua, S. S.; DeMayo, F. J.; Tsai, S. Y. Induction of mammary gland hyperplasia in transgenic mice overexpressing human Cdc25B. Oncogene 1999, 18, 4564-4576.
12. Yao, Y.; Slosberg, E. D.; Wang, L.; Hibshoosh, H.; Zhang, Y.-J.; Xing, W.-Q.; Santella, R. M.; Weinstein, I. B. Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice. Oncogene 1999, 18, 5159-5166.
13. Wu, F. Y.-H.; Sun, T. P. Vitamin K3 induces cell cycle arrest and cell death by inhibiting cdc25 phosphatase. Eur. J. Cancer 1999, 35, 1388-1393.
14. Tamura, K.; Rice, R. L.; Wipf, P.; Lazo, J. S. Dual G1 and G2/M phase inhibition by SC-9, a combinatorially derived Cdc25 phosphatase inhibitor. Oncogene 1999, 18, 6989-6996.
15. Tamura, K.; Southwick, E. C.; Kerns, J.; Rosi, K.; Carr, B. I.; Wilcox, C.; Lazo, J. S. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res. 2000, 60, 1317-1325.
16. Takahashi, M.; Dodo, K.; Sugimoto, Y.; Aoyagi, Y.; Yamada, Y.; Hashimoto, Y.; Shirai, R. Synthesis of the novel analogues of dysidiolide and their structure-activity relationship. Bioorg. Med. Chem. Lett. 2000, 10, 2571-2574.
17. Peng, H.; Zalkow, L. H.; Abraham, R. T.; Powis, G. Novel Cdc25A phosphatase inhibitors from pyrolysis of 3-alpha-azido-B-homo-6-oxa-4-cholesten-7-one on silica gel. J. Med. Chem. 1998, 41, 4677-4680.
18. Carnero, A. Targeting the cell cycle for cancer therapy. Br. J. Cancer 2002, 87, 129-133.
19. Lyon, M. A.; Ducruet, A. P.; Wipf, P.; Lazo, J. S. Dual-specificity phosphatases as targets for antineoplastic agents. Nat. Rev. Drug Discovery 2002, 1, 961-976.
20. Gunasekera, S. P.; McCarthy, P. J.; Kelly-Broger, M.; Lobkovsky, E.; Clardy, J. Dysidiolide: A novel protein phosphatase inhibitor from Caribbean Spongs Diysidea ehterria de Laubenfels. J. Am. Chem. Soc. 1996, 118, 8759-8760.
21. Blanchard, J. L.; Epstein, D. M.; Boisclair, M. D.; Rudolph, J.; Pal, K. Dysidiolide and Related γ-Hydroxy Butenolide Compounds as Inhibitors of the Protein Tyrosine Phosphatase, Cdc25. Bioorg. Med. Chem. Lett. 1999, 9, 2537-2538.
22. Cebula, R. E.; Blanchard, J. L.; Boisclair, M. D.; Mansuri, M. M.; Pal, K.; Bockovich, N. J. Synthesis and phosphatase activity of analogues of sulfiricin. Bioorg. Med. Chem. Lett. 1997, 7, 2015-2020.
23. Juan, C. C.; Wu, F. Y. Vitamin K3 inhibits growth of human hepatoma HepG2 cells by decreasing activities of both p34cdc2 kinase and phosphatase. Biochem. Biophys. Res. Comm. 1993, 190, 907-913.
24. Rice, R. L.; Rusnak, J. M.; Yokokawa, F.; Messner, D. J.; Boynton, A. L.; Wipf, P.; Lazo, J. S. A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variations. Biochem. 1997, 36, 15965-15974.
25. Bergnes, G.; Gilliam, C. L.; Boisclair, M. D.; Blanchard, J. L.; Blake, K. V.; Epstein, D. M.; Pal, K. Generation of an Ugi library of phosphate mimic-containing compounds and identification of novel dual specificity phosphatase inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 2849-2854.
26. Peng, H.; Xie, W.; Otterness, D. M.; Cogswell, J. P.; McConnel, R. T.; Carter, H. L.; Powis, G.; Abraham, R. T.; Zalkow, L. H. Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase. J. Med. Chem. 2001, 44, 834-848.
27. Lazo, J. S.; Aslan, D. C.; Southwick, E. C.; Cooley, K. A.; Ducruet, A. P.; Joo, B.; Vogt, A.; Wipf, P. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J. Med. Chem. 2001, 44, 4042-4049.
28. Lazo, J. S.; Nemoto, K.; Pestell, K. E.; Cooley, K.; Southwick, E. C.; Mitchell, D. A.; Furey, W.; Gussio, R.; Zaharevitz, D. W.; Joo, B.; Wipf, P. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol. Pharmacol. 2002, 61, 720-728.
29. Pu, L.; Amoscato, A. A.; Bier, M. E.; Lazo, J. S. Dual G1 and G2 Phase Inhibition by a Novel, Selective Cdc25 Inhibitor 7-Chloro-6-(2-morpholin-4-ylethylamino)-quinoline-5,8-dione. J. Biol. Chem. 2002, 277, 46877-46885.
30. Rudolph, J. The Catalytic Mechanism of Cdc25. Biochem. 2002, 41, 14613-14623.
31. Savitsky, P. A.; Finkel, T. Redox regulation of Cdc25C. J. Biol. Chem. 2002, 277, 20535-20540.
32. Fauman, E. B.; Cogswell, J. P.; Lovejoy, B.; Rocque, W. J.; Holmes, W.; Montana, V. G.; Piwnica-Worms, H.; Rink, M. J.; Saper, M. A. Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell 1998, 93, 617-625.
33. Reynolds, R. A.; Yem, A. W.; Wolfe, C. L.; Deibel, M. R. J.; Chidester, C. G.; Watenpaugh, K. D. Crystal Structure of the Catalytic Subunit of Cdc25B Required for G2/M Phase Transition of the Cell Cycle. J. Mol. Biol. 1999, 293, 559-568.
34. Rudolph, J.; Epstein, D.; Parker, L.; Eckstein, J. Specificity of natural and artifical substrates for human Cdc25A. Anal. Biochem. 2001, 289, 43-51.
35. Pirrung, M. C.; Deng, L.; Li, Z.; Park, K. Synthesis of 2,5-dihydroxy-3-(indol-3yl)benzoquinones by acid-catalyzed condensation of indoles with 2, 5 dichlorobenzoquinone. J. Org. Chem. 2002.
36. Makosza, M.; Bjaleki, M. Nitroarylamines via the Vicarious Nucleophilic Substitution of Hydrogen: Amination, Alkylamination, and Arylamination of Nitroarenes with Sulfenamides. J. Org. Chem. 1998, 63, 4878-4888.
37. Liedholm, B. Copper(I) catalyzed replacement of iodine by chloride ion in halonitrobenzenes. Acta Chem. Scand. 1971, 25, 113-117.
38. DiFabrio, R.; Alvaro, G.; Bertani, B.; Giacobbe, S. Straightforward synthesis of new tetrahydroquinoline derivatives. Can. J. Chem. 2000, 78, 809-815.
39. Chen, W.; Wilborn, M.; Rudolph, J. Dual-specific Cdc25B phosphatase: in search of the catalytic acid. Biochemistry 2000, 39, 10781-10789.
40. Wilborn, M.; Free, S.; Ban, A.; Rudolph, J. The C-Terminal Tail of the Dual-Specificity Cdc25B Phosphatase Mediates Modular Substrate Recognition. Biochemistry 2001, 40, 14200-14206.
41. Cleland, W. W. Statistical analysis of enzyme kinetic data. Methods Enzymol. 1979, 63, 103-138.
42. Heintz, N.; Sive, H. L.; Roeder, R. G. Regulation of human histone gene expression: kinetics of accumulation and changes in the rate of synthesis and in the half-lives of individual histone mRNAs during the HeLa cell cycle. Mol. Cell. Biol. 1983, 3, 539-550.
43. Preusch, P. C.; siegel, D.; Gibson, N. W.; Ross, D. A note on the inhibition of DT-diaphorase by dicoumarol. Free Radicals Biol., Med. 1991, 11, 77-80.
44. Gottlin, E.; Epstein, D. M.; Eckstein, J.; Dixon, J. Kinetic analysis of the catalytic domain of human Cdc25B. J. Biol. Chem. 1996, 272, 27445-27449.
45. Gant, T. W.; Rao, D. N.; Mason, R. P.; Cohen, G. M. Redox cycling and sulphydryl arylation; their relative importance in the mechanism of quinone cytotoxicity to isolated hepatocytes. Chem. Biol. Interact. 1988, 65, 157-173.
46. Jaffar, M.; Naylor, M. A.; Robertson, N.; Stratford, I. J. Targeting hypoxia with a new generation of indolequinones. Anticancer Drug Des. 1988, 13, 593-609.
47. Finley, K. T. The addition and substitution chemistry of quinones; Patai, S., Ed.; John Wiley: London, 1974; p 878.
48. Liu, K.; Xu, L.; Szalkowski, D.; Li, Z.; Ding, V.; Kwei, G.; Huskey, S.; Moller, D. E.; Heck, J. V.; Zhang, B. B.; Jones, A. B. Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor. J. Med. Chem. 2000, 43, 3487-3494.
49. Szabó, Z.; Kovács, A. Hydrogen bonding and molecular vibrations of 2,5-dihydroxy-1,4-benzoquinone. J. Mol. Struct. 1999, 510, 215-225.
50. Hill, A. V. The possible effects of the aggregation of the molecules of haemoglobin on its biochemical and other systems. J. Physiol. (London) 1910, 40, iv-vii.
51. Adair, G. S. The hemoglobin system. VI. The oxygen dissociation curve of hemoglobin. Chemistry 1925, 63, 529-545.
52. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening. J. Med. Chem. 2002, 1712-1722.
53. Chapman, R. G.; Ostuni, E.; takayama, S.; Holmlin, R. E.; Yan, L.; Whitesides, G. M. Surveying the surfaces that resist adsorption of proteins. J. Am. Chem. Soc. 2000, 122, 8303-8304.